Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M. Carter, E. Aubrey Thompson, Roberto A. Leon‐Ferre et al.|Nature Communications|2023Cited by 44
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Clinical Cancer Research|2020Cited by 41
Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial).Saranya Chumsri, E. Aubrey Thompson, Karama Asleh et al.|Journal of Clinical Oncology|2019Cited by 1
Supplementary Data S1-S9 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, E. Aubrey Thompson et al.|Unknown|2023Cited by 0
Supplementary Figure S4 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical TrialKarama Asleh, Saranya Chumsri, Heather Ann Brauer et al.|Unknown|2023Cited by 0